NCT05036798 2022-09-07
Tislelizumab+Lenvatinib+Gemox Regiment for Potentially Resectable Locally Advanced Malignant Tumors of Biliary System.
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
Clinical Trials
1 trialsPotentially Resectable Locally Advanced Malignant Tumors of Biliary System × tislelizumab × Gastrointestinal × Clear all